Back to Journals » Research and Reports in Tropical Medicine » Volume 15

The Spectrum of Ocular Diseases in the Onchocerciasis-Endemic Focus of Raga in South Sudan

Authors Sube KL, Lako JDW, Tongun JB, Gerber T, Mamur JP, Hamid Moto SJ, Jada SRL, Siewe Fodjo JN , Hopkins AD, Mackenzie CD, Colebunders R 

Received 22 August 2024

Accepted for publication 13 November 2024

Published 24 December 2024 Volume 2024:15 Pages 111—121

DOI https://doi.org/10.2147/RRTM.S481554

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Dr Mario A. Rodríguez-Pérez



Kenneth Lado Sube,1 Joseph Daniel Wani Lako,2 Justin Bruno Tongun,3 Tatjana Gerber,4 Jurel Payii Mamur,4 Sekonjo Juliano Hamid Moto,4 Stephen Raimon Legge Jada,5 Joseph Nelson Siewe Fodjo,6 Adrian Dennis Hopkins,7 Charles D Mackenzie,8,9 Robert Colebunders6,10

1Department Ophthalmology, College of Medicine, University of Juba, Juba, South Sudan; 2Department of Biotechnology, College of Applied and Industrial Sciences, University of Juba, Juba, South Sudan; 3Department of Pediatrics and Child Health, College of Medicine, University of Juba, Juba, South Sudan; 4Catholic Diocese of Wau, Wau, Western Bahr El Ghazal State, South Sudan; 5Amref Health Africa, Juba, South Sudan; 6Global Health Institute, University of Antwerp, Antwerp, Belgium; 7Neglected and Disabling Diseases of Poverty Consultant, Gravesend, Kent DA11 OSL, UK; 8Cor-NTD, Task Force for Global Health, Atlanta, Georgia, USA; 9The END Fund, Neglected Tropical Diseases, New York, NY, USA; 10Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, UK

Correspondence: Robert Colebunders, Global Health Institute, University of Antwerp, Antwerp, Belgium, Email [email protected]

Introduction: Raga County is an onchocerciasis-endemic area in the Western Bahr El Ghazal state of South Sudan, known to have a high prevalence of blindness. The objective of this study was to determine the causes of eye disease and blindness in Raga County as well as to assess the relationship of eye diseases with other prevalent conditions like onchocerciasis and epilepsy.
Methods: We reviewed unpublished pre-community directed treatment with ivermectin (CDTI) data about eye disease and onchocerciasis in Western Bahr El Ghazal including Raga. In addition, a cross-sectional study was conducted from 21st March to 2nd April 2023 in 11 villages in Raga County. Participants were persons with blindness or other eye/vision problems, recruited via a community-based approach. Two senior ophthalmic clinical officers, supervised by an experienced ophthalmologist, performed the following assessments on participants: visual acuity measurement with Snellen Charts, anterior chamber examination with a loupe, and fundoscopy to assess the posterior segment with direct and indirect ophthalmoscopes.
Results: Pre-CDTI data showed that the most severe vision problems in villages with a high prevalence of O. volvulus infection were caused by onchocerciasis eye disease. During the 2023 survey, in total, 1559 persons (3,118 eyes) were examined (mean age: 47 ± 19.2 years, 58.4% male). The most frequent eye diagnosis was allergic conjunctivitis, observed in 1453 (46.6%) eyes of the participants. The main causes of blindness were onchocerciasis-related blindness (22.6%, caused by onchocerciasis chorioretinitis (9.4%), sclerosing keratitis, punctate keratitis (5.6%), and onchocerciasis optic neuropathy (7.6%)), and cataract (9.3%). A significantly higher proportion of persons with epilepsy presented with clinical signs of onchocerciasis including blindness (53.2%), compared to persons without epilepsy (32.5%) (p = 0.0007).
Conclusion: Despite years of CDTI, the main causes of blindness in Raga County remain onchocerciasis-related blindness observed in 22.6% and cataract observed in 9.3% of the study participants. The study confirmed an epidemiological association between onchocerciasis and epilepsy.

Keywords: Onchocerciasis, ocular disease, blindness, epilepsy, nodding syndrome, ivermectin

Introduction

Onchocerciasis (also known as river blindness) is a neglected tropical disease caused by the filarial worm, Onchocerca volvulus, which is transmitted by blackflies of the genus Simulium.1 The disease is transmitted through daytime biting female blackflies. Black flies pass through four stages in their development - egg, larva, pupa to reach the last stage of an adult fly. Eggs are deposited by female flies onto submerged plants or rocks, and the developing fly moves through the stages to emerge as adult 9–20 days later depending largely on environmental circumstances. These vectors live from 3–4 weeks.2

The causative nematode, Onchocerca volvulus, passes through five stages in its development; three stages are in the vector black fly. In taking a blood meal, the black acquires the first stage, the L1 (microfilariae) stage, which develops in the body of the fly to become an infective larva (L3 stage in the head of the fly ready for passage back into humans on the next blood meal the fly takes. This intra-vector development takes some 7–9 days (1).

Following the infecting fly bite, the L3 stage will, over the next 6–12 months, pass through the L4 stage to reach the adult form as either a male or female worm; the adult stages can be found in fibro-vascular granulomas palpable on boney prominences such as the dermal tissues over the iliac crest and the rib cage. Fertilized female worms produce millions of microfilariae and these migrate from the nodules to the skin and eyes. The adult O volvulus worms can live for up to 12 years.2

Ivermectin is currently the only readily available microfilaricidal drug that kills microfilariae but does not kill the female adult worm producing the microfilaria. It only and temporarily sterilises female adult worms. Therefore, the ivermectin mass drug administration needs to be given to a population for at least 15 years, the lifespan of the microfilariae. Moreover, to eliminate onchocerciasis, during each community directed treatment with ivermectin (CDTI) a therapeutic coverage of at least 80% is needed.2

South Sudan is among the African countries that are most affected by onchocerciasis, with the disease being endemic in around half (49%) of the country.3 By 2022, over nine million South Sudanese were estimated to live in areas requiring preventive chemotherapy for the disease through CDTI.4 The highly endemic foci of onchocerciasis in South Sudan are found in Western Equatoria, Northern and Western Bahr El Ghazal areas, and part of Central Equatoria.5 A CDTI program was initiated in Western Bahr El Ghazal in 2005.6 However, the programs faced low coverage and interruptions due to insecurity.

Onchocerciasis is mostly known as a skin and eye disease but there is increasing epidemiological evidence for an association between onchocerciasis and epilepsy, particularly in areas with sub-optimal onchocerciasis elimination programmes.7 A high epilepsy prevalence was already reported in Western Equatoria as early as 1946.8 In the 1990s the first cases of nodding syndrome were recognized.9 Door-to-door surveys conducted in Western Equatoria between 2018 and 2021 revealed an epilepsy prevalence of 4.4% in Maridi,10 5.8% in Mvolo,11 and 3.3% in Mundri.12 A high prevalence of blindness was also documented in these sites, notably 2.8% in Mvolo11 and 2.7% in Mundri.12

Severe ocular onchocerciasis is well known in the north western corner of South Sudan, as was demonstrated in various epidemiological surveys13 and major therapeutic studies14,15 carried out in Bahr El Ghazal in the late 1970s and the early 1980s.

According to observations by the Ophthalmological Association of South Sudan, it was estimated that 80 to 85% of the eye patients from Raga County suffer from blindness due to complications of onchocerciasis. However, this was never investigated in a scientific study. In 2021, the Health Department of the Catholic Diocese of Wau conducted a health assessment in all parishes within the Catholic Dioceses of Wau. Parishes in Raga County reported high numbers of blind people and people with epilepsy. The objectives of this study were to document in detail the ocular pathologies encountered in Raga County, to determine the causes of eye disease and blindness in these sites, and to assess the relationship between onchocerciasis and epilepsy. We also reviewed historical unpublished data about onchocerciasis eye lesions observed in Western Bahr El Ghazal.

Methodology

Ophthalmological Data Pre-CDTI in Western Bahr El Ghazal

We reviewed unpublished ophthalmological data collected during a survey in six villages in Western Bahr El Ghazal and in hospitals in Raga (in 1985) and Wau (in 1981–84).13 Village surveys were carried out using standard procedures as previously described13 (Figure 1).

Figure 1 (A) Location of the 6 villages surveyed for ocular disease in 1979–1984 in the Western Bahr El Ghazal area (blue rectangle on map B) (B) Map of South Sudan.

Individuals were assessed by skin snip, and visual acuity (Tumbling “E” Chart system). Those with a visual acuity worse than 20/60 were further examined at the hospital of Raga and Wau for confirmatory visual acuity assessment, assessment of onchocercal corneal lesions, and presence of mf in the anterior chamber.

Eye Survey

Study Design and Period

We conducted a community-based, cross-sectional study from 21st March to 2nd April 2023.

Study Setting

The study was conducted in the Raga County, Western Bahr El Ghazal State, South Sudan. Raga County has six fast-flowing rivers and many seasonal streams which serve as breeding sites for the blackflies. The main river is the Jur River. In Raga, onchocerciasis is known as Jur River Blindness transmitted by the blackflies belonging to the genus Simulium damnosum.16 Demographically, the population of Raga was estimated at 59,638 individuals in 2022.17 Most residents are engaged in farming (groundnut, cassava, sesame, sorghum, maize, vegetables, millet, and tobacco), animal rearing (goats and poultry), and fishing.

Study Villages and Participants

Within the parishes of Raga County, villages with a prayer center/church and a catechist in charge of the congregation were selected. This facilitated the mobilization of community members, as we used the churches as recruitment sites in these villages. Selected villages were: Abulu, Boro Madina, Deim Zubeir, Ferika and Timsah, Kata, Kuru, Magayat, Raga, Sira-Malaga, and Sopo. Residents in the study villages who were blind or were having an eye problem were eligible to participate in the study, regardless of their ages and sex.

Study Procedure

Community mobilizers were trained by the research team on how to mobilize the community and refer eligible individuals to the church/prayer center for enrolment in the study. Consenting study participants were interviewed and examined by the research team, comprised one experienced ophthalmologist (KLLS) as team leader and two senior ophthalmic clinical officers (DM, ML). Data were collected using a standardized questionnaire which included questions about demographic characteristics, eye symptoms, history of itching, history of epilepsy and family history of epilepsy. The data collection tool also had a section to document findings from the clinical and ophthalmological examination of participants as described below.

Examinations of the participants included visual acuity measurement with Snellen Charts, anterior chamber examination with a loupe, and fundoscopy to assess the posterior segment with direct and indirect ophthalmoscopes. Persons with poor vision without anterior pathology along the visual axis (corneal scar, corneal dystrophies, and cataract) qualified for fundoscopy after dilation with 5% tropicamide drops. Persons with cup and disc ratio >0.5 were classified as having glaucoma. Patients diagnosed with treatable conditions were given medications and counseling. Meanwhile, those with permanent untreatable conditions were counseled and advised accordingly about the prognosis of their conditions. Surgical conditions were referred to Wau Teaching Hospital for free eye surgery.

A person was considered to have onchocerciasis if he/she presented characteristic clinical manifestations such as onchocerciasis skin lesions (hypopigmented areas, nodules), itching, and eye lesions (keratitis, chorioretinitis, optic neuropathy, etc). No skin snip nor O. volvulus antibody test was performed.

A person was considered to present blindness caused by onchocerciasis if he/she had a visual acuity of zero and also presented one of the following conditions: sclerosing keratitis, punctate keratitis, maculopathy, and optic neuropathy.

A person was considered to have epilepsy if he/she or a family member reported that the person presented epileptic seizures, in accordance with Question 5 of the validated epilepsy screening questionnaire of Diagana et al.18

Data Analysis

The collected data were entered into an Excel spreadsheet and later transferred to SPSS version 21. Descriptive statistics were conducted, with categorical variables presented as counts and percentages. Comparisons across groups were done using the Pearson’s Chi-squared test or Fisher’s exact test as appropriate, with a significance threshold of 0.05.

Ethics Statement

Ethical approval was obtained from the ethics committee of the Ministry of Health of South Sudan (January 2018, MOH/ERB50/2019) and from the ethics committee of the Antwerp University Hospital, Belgium (April 2019, B300201940004). All research procedures followed the Good Clinical Practices and the Declaration of Helsinki. Prior to conducting the study, local village representatives were consulted, and approval for the study was obtained. Verbal informed consent, in the presence of a witness, was obtained from all participants including from the parents/guardians of participating children and all data treated confidentially. Approval for verbal informed consent from the participants was obtained from the ethics committees.

Results

Ophthalmological Data Pre-CDTI in Western Bahr EL Ghazal

A very high prevalence of O. volvulus infection was observed in selected villages in the central Western Bahr El Ghazal area (Table 1). Moreover, most of the persons with a visual acuity worse than 20/50 presented onchocerciasis ocular disease. Of the 35 persons examined at Raga hospital, all presented onchocerciasis cornea lesions and microfilaria in the anterior eye chamber and of 156 persons examined at Wau hospital 143 (91.6%) presented onchocerciasis cornea lesions and 148 (94.8%) with microfilaria in the anterior eye chamber, 21 of these had >50 microfilaria in the anterior chamber.

Table 1 Prevalence of O. volvulus Infection Observed During Eye Surveys in Selected Villages in the Central Western Bahr El Ghazal Area

2030 Survey

In total 1,559 persons (3,118 eyes) were examined, 58.4% (911) males and 41.6% (648) females with a mean age of 47.8 ± 19.2 years. The most represented age group was 40–49-year, accounting for 21.2% (331) of the study population. Overall, 635 (40.7%) participants were residents of Raga town (Table 2).

Table 2 Demographic Characteristics of 1,559 Persons with Eye Problems in Raga County, 2023

The most frequent eye diagnosis was allergic conjunctivitis observed in 1,453 (46.6%) of the eyes of participants (Table 3). The main causes of blindness were onchocerciasis-related blindness (22.6%) (onchocerciasis chorioretinitis (9.4%), corneal scar/dystrophies (5.6%), and onchocerciasis optic neuropathy (7.6%)). Other ocular blindness is due to cataract (9.3%) and glaucoma (4.8%).

Clinical manifestations of onchocerciasis were observed in one-third of participants: 520/1,559 (33.4%). Furthermore, 62 (4.0%) of participants were reported to have epilepsy, while a family history of epilepsy was reported in 181 (11.6%) participants. Age-specific clinical findings are summarized in Table 3 and reveal a peak epilepsy prevalence of 11.5% in the 10–19 years age group. Meanwhile, the age-specific prevalence of onchocerciasis clinical manifestations steadily increased with age to reach a maximum of 47.2% in the ≥70-year-old age group (Table 4).

Table 3 Eye Diagnosis of 1,559 Persons with an Eye Problem (n = 3,118 Eyes Examined) in Raga County, 2023

Table 4 History of Clinical Onchocerciasis and Epilepsy in the Study Participants by Age Group in Raga County, 2023

A significantly higher proportion of persons with epilepsy presented onchocerciasis clinical manifestations (53.2%) compared to persons without epilepsy (32.5%); Chi-square without Yates correction p = 0.0007 (Table 5).

Table 5 Association of Clinical Manifestations of Onchocerciasis* and Epilepsy

Discussion

Our review of unpublished ophthalmological data collected pre-CDTI in Western Bahr El Ghazal and the 2023 eye survey data show the importance of onchocerciasis ocular disease burden in Raga County. The pre-CDTI data showed that the most severe vision problems in villages with a high prevalence of O. volvulus infection were caused by onchocerciasis eye disease.

During the 2023 survey, the most frequently observed eye disease was conjunctivitis. This conjunctivitis was most likely the consequence of the presence of O. volvulus microfilariae in the conjunctiva. This may lead to itching and conjunctivitis, characterized by increased pigmentation around the limbus, some redness of the conjunctiva and conjunctival discharge. Other onchocerciasis-related manifestations among the participants included: onchocerciasis chorioretinitis and optic neuropathy observed in, respectively, 9.2% and 7.6% of the participants, and corneal scars and dystrophies and vernal kerato-conjunctivitis observed in, respectively, 5.6% and 0.6% of the participants. Cataracts were observed in 9.3% and glaucoma in 4.8% of the participants; these two conditions have been reported to be associated with onchocerciasis (17).

However, it remains unclear what exact proportion of cataract and glaucoma in our study population can be attributed to onchocerciasis. Existing literature describes the following major ophthalmological findings that can be caused by onchocerciasis: corneal changes, such as sclerosing keratitis and snowflake opacities; torpid iritis characterized by typical pear-shaped deformity of the iris; secondary cataracts; chorioretinopathy; and optic neuritis.19–21 Major causes of blindness caused by onchocerciasis are sclerosing keratitis and chronic torpid iritis, chorioretinopathy, and optic neuropathy.19–21 When mf dies, the host immunological response causes ocular inflammation leading to progressive loss of vision and eventually blindness.1,19,22,23 Death of individual microfilariae within the cornea is associated with snowflake opacities, and massive death will lead to sclerosing keratitis.19

The pathogenesis of chorioretinal changes in onchocerciasis is still controversial. It has been suggested that autoimmune reactions involving cross-reacting antigens between O. volvulus and interphotoreceptor retinoid-binding proteins and immune complex deposition may play a role,24–26 but this has not been confirmed. Ivermectin intake is expected to reduce the number of microfilariae in the anterior chamber of the eye and indirectly reduce the inflammation. However, ivermectin may not reverse severe or long-standing damage to the eyes, in particular, the choroid and retina.

A high proportion of the participants reported to have epilepsy (4.0%) or reported a family history of epilepsy (11.6%). This self-reported epilepsy prevalence was similar to the observed epilepsy prevalence in the general population in other onchocerciasis-endemic areas such as Maridi,10 Mundri,12 and Mvolo.11 Importantly, a significantly higher proportion of persons with epilepsy presented onchocerciasis clinical manifestations (53.2%) compared to persons without epilepsy (32.5%) suggesting that also in Raga, similar to other onchocerciasis-endemic areas with high O. volvulus transmission, onchocerciasis is associated with epilepsy.27

The strength of our 2023 study is that a large number of persons with eye problems in an onchocerciasis-endemic area with limited past exposure to ivermectin were investigated by two senior ophthalmic clinical officers supervised by an experienced ophthalmologist (KLLS).

However, our study also has several limitations. Most importantly, the diagnosis of onchocerciasis was only made based on clinical manifestations and no O. volvulus antibody test nor skin snip testing was performed. Also, slit-lamp examination to identify microfilariae in the anterior chamber was not performed. However, the ocular manifestations observed in 2023 were comparable with the observations pre-CDTI. CDTI was implemented in South Sudan in 2004, but therapeutic coverage has been low, and there have been interruptions because of insecurity and the COVID-19 pandemic. Therefore, most likely also in 2023, a large proportion of the visual problems in Raga were caused by onchocerciasis.

Only persons with eye problems were examined. Therefore, we do not have data about the prevalence of blindness and eye problems in the investigated communities. Moreover, only self-reported data about epilepsy was collected with no clinical confirmation of the diagnosis, and thus must be interpreted with caution. Finally, no history about previous ivermectin intake was obtained.

Conclusion

In 2023, despite more than 15 years of CDTI, the main cause of blindness in Raga County is still onchocerciasis-related ocular disease, observed in 22.6% of the persons with eye disease. Onchocerciasis clinical signs (eye disease) were more frequent among persons with epilepsy, supporting an epidemiological association between the two conditions. Furthermore, epilepsy was most common among the 10–19-year-old which is consistent with onchocerciasis-associated epilepsy.7 The overall high onchocerciasis-related morbidity (blindness and epilepsy) suggests that there is high ongoing O. volvulus transmission in Raga County. The latter is most likely because of low CDTI coverage. A population-based study needs to be conducted to determine the exact prevalence of onchocerciasis, blindness, and epilepsy in Raga County. Nevertheless, to reduce the onchocerciasis-associated morbidity in Raga County, the onchocerciasis elimination program needs to be strengthened. It will be very important to obtain high ivermectin intake among children 5–18 years to protect them to develop onchocerciasis-associated epilepsy.27,28 Two recently published studies conducted in onchocerciasis-endemic areas, one in Maridi in South Sudan,29 and the other in Mahenge in Tanzania30 have shown that switching from annual to bi-annual CDTI was able to obtain an important decrease in the incidence of epilepsy. There is now robust epidemiological evidence that onchocerciasis is associated with epilepsy in areas with high O. volvulus transmission.7,27,31,32

In 2023, bi-annual CDTI was initiated, but the challenge will be to continue this program with high ivermectin therapeutic coverage. Moreover, an eye unit needs to be established at the Raga County hospital where screening and managing of simple eye diseases can be done as well as referring or booking surgical cases. Community workers need to be trained in eye care services and a cataract surgical eye camp will need to be organized at regular intervals. In addition, epilepsy treatment centers need to be established in the area where anti-seizure medication could be provided free of charge by trained primary health care workers.

Author Summary

Data obtained in South Sudan in Western Bahr El Ghazal, including Raga County, before the introduction of Community Directed Treatment with Ivermectin (CDTI) showed that the most severe vision problems in villages with a high prevalence of O. volvulus infection were caused by onchocerciasis eye disease. In 2023, despite more than 15 years of CDTI in a survey in Raga County among 1, 559 persons with eye diseases, onchocerciasis-related blindness, specifically onchocerciasis chorioretinitis, sclerosing keratitis and dystrophy, maculopathy, and optic neuropathy, remained a leading cause of visual impairment. Onchocerciasis-related clinical symptoms (including ocular problems) were more frequent among persons with epilepsy compared to their non-epileptic counterparts. This highlights the urgency to strengthen the onchocerciasis elimination program by increasing ivermectin treatment coverage, and the establishment of eye care and epilepsy treatment centers in the affected region.

Data Sharing Statement

Data will be made available by the corresponding author upon reasonable request.

Acknowledgments

We thank the Catholic Diocese of Wau, the parishes of Raga County and the administrators of Raga County for their support. We also thank the team members: Deng Makur, Martin Loki, Sister Tibberiah, for their cooperation.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

RC and JNSF received funding from the Research Foundation – Flanders (FWO), grant number G0A0522N and 1296723N, respectively. KLLS received funding from the European Society of Cataract and Refractive Surgeons.

Disclosure

The authors have declared that no competing interests exist.

References

1. Brattig NW, Cheke RA, Garms R. Onchocerciasis (river blindness) - more than a century of research and control. Acta Trop. 2021;218:105677. PMID: 32857984. doi:10.1016/j.actatropica.2020.105677

2. WHO. World Health Organization. Guidelines for Stopping Mass Drug Administration and Verifying Elimination of Human Onchocerciasis. 2006. Available from: https://apps.who.int/iris/handle/10665/204180. Accessed December 5, 2024

3. Noma M, Zoure HG, Tekle AH, Enyong PA, Nwoke BE, Remme JH. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (1) priority areas for ivermectin treatment. Parasit Vectors. 2014;7:325. doi:10.1186/1756-3305-7-325

4. World Health Organisation Africa. Expanded Special Project for Elimination of Neglected Tropical Diseases: South Sudan - Onchocerciasis 2022. 2022. Available from: https://espen.afro.who.int/countries/south-sudan. Accessed December 5, 2024

5. Abd-Elfarag G, Logora MY, Carter JY, et al. The effect of bi-annual community-directed treatment with ivermectin on the incidence of epilepsy in onchocerciasis endemic villages in South Sudan: a study protocol. Infect Dis Poverty. 2018;7(1):112. doi:10.1186/s40249-018-0496-2

6. African Programme of Onchocerciasis Control (APOC). Western Bahr El Ghazal CDTI project 2005. Available from: https://iris.who.int/bitstream/handle/10665/362486/362486-eng.pdf?sequence=1&isAllowed=y. Accessed December 5, 2024

7. Colebunders R, Njamnshi AK, Menon S, et al. Onchocerca volvulus and epilepsy: a comprehensive review using the Bradford Hill criteria for causation. PLoS Negl Trop Dis. 2021;15(1):e0008965. PMID: 33411705. doi:10.1371/journal.pntd.0008965

8. Kirk R, Morgan HV, Haseeb MA, Satti MH. Onchocerciasis in the Sudan Republic. Ann Trop Med Parasitol. 1959;53(1):97–102. PMID: 13650495. doi:10.1080/00034983.1959.11685905

9. Tumwine JK, Vandemaele K, Chungong S, et al. Clinical and epidemiologic characteristics of nodding syndrome in Mundri County, southern Sudan. Afr Health Sci. 2012;12(3):242–248. PubMed PMID: 23382736. doi:10.4314/ahs.v12i3.1

10. Colebunders R, YC J, Olore PC, et al. High prevalence of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan: a community-based survey. Seizure. 2018;63:93–101. PMID: 30468964. doi:10.1016/j.seizure.2018.11.004

11. Raimon S, Dusabimana A, Abd-Elfarag G, et al. High Prevalence of Epilepsy in an Onchocerciasis-Endemic Area in Mvolo County, South Sudan: a Door-To-Door Survey. Pathogens. 2021;10(5). PMID: 34068976. doi:10.3390/pathogens10050599

12. Jada SR, Dusabimana A, Abd-Elfarag G, et al. The Prevalence of Onchocerciasis-Associated Epilepsy in Mundri West and East Counties, South Sudan: a Door-to-Door Survey. Pathogens. 2022;11(4). PMID: 35456071. doi:10.3390/pathogens11040396

13. Mackenzie CD, Williams JF, O’Day J, Ghalal I, Flockhart HA, Sisley BM. Onchocerciasis in southwestern Sudan: parasitological and clinical characteristics. Am J Trop Med Hyg. 1987;36(2):371–382. PMID: 3826496. doi:10.4269/ajtmh.1987.36.371

14. Hutchinson DB, El-Sheikh H, Jones BR, Anderson J, Fuglsang H, Mackenzie CD. Adverse reactions to cutaneous diethylcarbamazine in onchocerciasis. Lancet. 1979;2(8132):46. PMID: 87926. doi:10.1016/s0140-6736(79)90215-0

15. Bird AC, el-Sheikh H, Anderson J, Fuglsang H. Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. Br J Ophthalmol. 1980;64(3):191–200. doi:10.1136/bjo.64.3.191

16. Lewis DJ. Simulium Damnosum and its relation to onchocerciasis in the Anglo-Egyptian Sudan. Bull Entomol Res. 1953;43(4):597–644.

17. African Programme of Onchocerciasis Control (APOC). Raja County, Western Bahr El-Ghazal State Demography 2022. Available from: https://www.csrf-southsudan.org/county_profile/raja/. Accessed December 5, 2024

18. Diagana M, Preux PM, Tuillas M, Ould Hamady A, Druet-Cabanac M. Dépistage de l’épilepsie en zones tropicales: validation d’un questionnaire en Mauritanie. Bull Soc Pathol Exot. 2006;99(2):103–107.

19. Babalola OE. Ocular onchocerciasis: current management and future prospects. Clin Ophthalmol. 2011;5:1479–1491. PubMed PMID: 22069350. doi:10.2147/OPTH.S8372

20. Hopkins AD. Ivermectin and onchocerciasis: is it all solved? Eye. 2005;19(10):1057–1066. PMID: 16304585. doi:10.1038/sj.eye.6701962

21. World Health Organisation. Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control. World Health Organ Tech Rep Ser. 1995;852:1–104.

22. Tamarozzi F, Wright HL, Johnston KL, Edwards SW, Turner JD, Taylor MJ. Human filarial Wolbachia lipopeptide directly activates human neutrophils in vitro. Parasite Immunol. 2014;36(10):494–502. PMID: 24909063. doi:10.1111/pim.12122

23. Tamarozzi F, Halliday A, Gentil K, Hoerauf A, Pearlman E, Taylor MJ. Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. Clin Microbiol Rev. 2011;24(3):459–468. PMCID: PMCPMC3131055. doi:10.1128/CMR.00057-10

24. McKechnie NM, Braun G, Klager S, et al. Cross-reactive antigens in the pathogenesis of onchocerciasis. Ann Trop Med Parasitol. 1993;87(6):649–652. PMID: 8122928. doi:10.1080/00034983.1993.11812824

25. Van der Lelij A, Doekes G, Hwan BS, et al. Humoral autoimmune response against S-antigen and IRBP in ocular onchocerciasis. Invest Ophthalmol Vis Sci. 1990;31(7):1374–1380. PMID: 2365568.

26. Paganelli R, Ngu JL, Levinsky RJ. Circulating immune complexes in onchocerciasis. Clin Exp Immunol. 1980;39(3):570–575. PMID: 7379329.

27. Van Cutsem G, Siewe Fodjo JN, Hadermann A, et al. Onchocerciasis-associated epilepsy: charting a path forward. Seizure. 2024. PMID: 38677953. doi:10.1016/j.seizure.2024.04.018

28. Colebunders R, Siewe Fodjo JN, Kamoen O, et al. Treatment and prevention of epilepsy in onchocerciasis-endemic areas is urgently needed. Infect Dis Poverty. 2024;13(1):5. PMID: 38212805. doi:10.1186/s40249-024-01174-8

29. Jada SR, Amaral LJ, Lakwo T, et al. Effect of onchocerciasis elimination measures on the incidence of epilepsy in Maridi, South Sudan: a 3-year longitudinal, prospective, population-based study. Lancet Glob Health. 2023;11(8):e1260–e8. PMID: 37474232. doi:10.1016/S2214-109X(23)00248-6

30. Bhwana D, Amaral LJ, Mhina A, et al. Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: a population-based prospective study. PLoS Negl Trop Dis. 2023;17(6):e0011178. PMID: 37379350. doi:10.1371/journal.pntd.0011178

31. Siewe Fodjo JN, Remme JHF, Preux PM, Colebunders R. Meta-analysis of epilepsy prevalence in West Africa and its relationship with onchocerciasis endemicity and control. Int Health. 2020;12(3):192–202. PMCID: PMCPMC7320426. doi:10.1093/inthealth/ihaa012

32. Vinkeles Melchers NVS, Mollenkopf S, Colebunders R, et al. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities. Infect Dis Poverty. 2018;7(1):101. doi:10.1186/s40249-018-0481-9

Creative Commons License © 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.